India is set to introduce low-cost generic versions of popular weight-loss medications, a development experts say could significantly reshape global efforts to combat obesity.
The move follows the expiration of key patents on Semaglutide, the active ingredient in widely used drugs such as Ozempic and Wegovy. With patent protections lapsing across multiple countries, Indian pharmaceutical manufacturers are preparing to launch more affordable alternatives.
Medical professionals in Mumbai report a growing demand for these treatments even before generics reach the market. Endocrinologists say patient numbers are expected to rise sharply once prices drop, reflecting strong interest in effective obesity management options.
Industry analysts note that by the end of 2026, patents on semaglutide will expire in at least ten countries, including Brazil, China, South Africa, Turkey, and Canada regions that together account for a significant share of the global obesity burden.
Indian drugmakers, including Zydus Lifesciences, have announced plans for immediate entry into the market, with projections suggesting that dozens of generic brands could become available within a short period.
The pricing shift is expected to be substantial. Current branded treatments cost significantly more, placing them out of reach for many patients. Generic versions, however, are projected to reduce monthly treatment costs by more than half, potentially expanding access to millions.
The development comes at a time when obesity rates are rising globally, including in India, where recent data show increasing numbers of both men and women classified as overweight or obese, even as the country continues to grapple with undernutrition.
Global health experts say the implications extend far beyond India. As one of the world’s largest suppliers of generic medicines particularly to low- and middle-income regions, including parts of Africa the country’s entry into the semaglutide market could improve access to effective obesity treatments worldwide.
However, specialists caution that while affordable medication is a major step forward, it is not a complete solution. They emphasize that long-term strategies, including improved diet, physical activity, and public health education, remain essential in addressing the root causes of obesity.
For many patients, the availability of lower-cost alternatives could be transformative, making sustained treatment more realistic and reducing the financial burden associated with long-term weight management.
and then